CN101808642B - 肥大细胞稳定剂治疗肥胖症 - Google Patents

肥大细胞稳定剂治疗肥胖症 Download PDF

Info

Publication number
CN101808642B
CN101808642B CN200880108966XA CN200880108966A CN101808642B CN 101808642 B CN101808642 B CN 101808642B CN 200880108966X A CN200880108966X A CN 200880108966XA CN 200880108966 A CN200880108966 A CN 200880108966A CN 101808642 B CN101808642 B CN 101808642B
Authority
CN
China
Prior art keywords
mice
mast cell
obesity
day
wat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880108966XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101808642A (zh
Inventor
施国平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of CN101808642A publication Critical patent/CN101808642A/zh
Application granted granted Critical
Publication of CN101808642B publication Critical patent/CN101808642B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880108966XA 2007-09-28 2008-09-24 肥大细胞稳定剂治疗肥胖症 Expired - Fee Related CN101808642B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96040807P 2007-09-28 2007-09-28
US60/960,408 2007-09-28
PCT/US2008/011026 WO2009045291A2 (en) 2007-09-28 2008-09-24 Mast cell stabilizers in the treatment of obesity

Publications (2)

Publication Number Publication Date
CN101808642A CN101808642A (zh) 2010-08-18
CN101808642B true CN101808642B (zh) 2012-05-02

Family

ID=40523802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880108966XA Expired - Fee Related CN101808642B (zh) 2007-09-28 2008-09-24 肥大细胞稳定剂治疗肥胖症

Country Status (5)

Country Link
US (2) US8445435B2 (enExample)
EP (1) EP2205243A4 (enExample)
JP (1) JP5460600B2 (enExample)
CN (1) CN101808642B (enExample)
WO (1) WO2009045291A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2766157A1 (en) 2009-06-25 2010-12-29 Hua Gong Methods for diagnosing irritable bowel syndrome
CN102204871A (zh) * 2011-06-01 2011-10-05 王青 一种减肥用组合物
CN102846679A (zh) * 2012-08-14 2013-01-02 王青 一种具有减肥作用的组合物
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634699A (en) * 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
CA2161777A1 (en) * 1993-05-10 1994-11-24 Nancy M. Gray Methods and compositions using optically pure (+)-zileuton
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6225327B1 (en) 1996-04-18 2001-05-01 Alcon Laboratories, Inc. Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complications
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
KR20010021625A (ko) * 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US20040259952A1 (en) * 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006122069A2 (en) * 2005-05-09 2006-11-16 Azur Pharma Formulations of mast cell stabilizing agents for delivery to the colon
EP2409973A1 (en) * 2006-02-21 2012-01-25 Critical Therapeutics, Inc. New crystal form and pharmaceutical compositions of (+)-R-zileuton
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers

Also Published As

Publication number Publication date
WO2009045291A3 (en) 2009-07-16
CN101808642A (zh) 2010-08-18
US8785383B2 (en) 2014-07-22
EP2205243A2 (en) 2010-07-14
JP2010540519A (ja) 2010-12-24
US20090093511A1 (en) 2009-04-09
US8445435B2 (en) 2013-05-21
JP5460600B2 (ja) 2014-04-02
EP2205243A4 (en) 2012-06-13
US20130231362A1 (en) 2013-09-05
WO2009045291A2 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CN101808642B (zh) 肥大细胞稳定剂治疗肥胖症
US8445437B2 (en) Treatment and prevention of cardiovascular disease using mast cell stabilizers
Ala et al. Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next?
Yan et al. MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation
Li et al. Hesperidin inhibits keratinocyte proliferation and imiquimod-induced psoriasis-like dermatitis via the IRS-1/ERK1/2 pathway
Mutoh et al. Loss of adiponectin promotes intestinal carcinogenesis in Min and wild-type mice
EP1811991B1 (en) Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
JP2020055868A (ja) ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
US20160015699A1 (en) Nitroxides for use in treating or preventing diabetes and obesity
Liao et al. Acteoside alleviates blood–brain barrier damage induced by ischemic stroke through inhibiting microglia HMGB1/TLR4/NLRP3 signaling
JP2004510705A (ja) 方法
EP2675275B1 (en) Compositions and methods for the treatment of obesity and related disorders
Moore et al. Kaempferol improves glucose uptake in skeletal muscle via an AMPK-dependent mechanism
Wang et al. Inhibition of nuclear factor kappa B inducing kinase suppresses inflammatory responses and the symptoms of chronic periodontitis in a mouse model
KR101642042B1 (ko) 티아졸리딘디온의 p35 및 p25 활성 변화에 대한 용도
CN110664815A (zh) 长春花碱iii在制备预防或治疗阿尔茨海默症药物中的应用
JP6284341B2 (ja) 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法
Cai et al. Catharanthine tartrate ameliorates osteoclastogenesis by destabilizing HIF-1α
WO2004009023A2 (en) Novel inhibitors of ubiquitin isopeptidases
WO2021053618A1 (en) Treatment comprising fxr agonists
Feng et al. The Effect and Mechanism of Thalidomide in Ameliorating Crohn’s Disease-Related Intestinal Fibrosis
Schroeder et al. Novel Interleukin-11 Inhibitors Attenuate Collagen Production in Patient-Derived Synovial Fibroblasts
EP3834888A2 (en) Agents for treatment of alcohol use disorder
Smithson Dysregulation of Nicotinamide Adenine Dinucleotide-Dependent Pathways as a Driver of Alcoholic Liver Fibrosis during Aging
CN117695274A (zh) 银杏内酯b在制备治疗血管内皮损伤的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120502

Termination date: 20190924